We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

112 hedge funds and large institutions have $1.52B invested in Clovis Oncology, Inc. in 2013 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 60 increasing their positions, 21 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 21

11% more capital invested

Capital invested by funds: $1.36B → $1.52B (+$153M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

3% less funds holding

Funds holding: 116112 (-4)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

34% less call options, than puts

Call options by funds: $9.63M | Put options by funds: $14.6M

Holders
112
Holders Change
-4
Holders Change %
-3.45%
% of All Funds
3.25%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
21
Increased
60
Reduced
21
Closed
25
Calls
$9.63M
Puts
$14.6M
Net Calls
-$4.98M
Net Calls Change
-$3.87M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$286M +$16.1M +296,200 +7%
PHS
2
PFM Health Sciences
California
$156M +$30.3M +556,600 +27%
NMC
3
NEA Management Company
Maryland
$137M
Vanguard Group
4
Vanguard Group
Pennsylvania
$75.7M +$12.1M +223,216 +22%
SCA
5
SAC Capital Advisors
Connecticut
$70.3M +$4.31M +79,325 +7%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$55M +$9.54M +175,300 +24%
BFA
7
BlackRock Fund Advisors
California
$50M +$4.86M +89,308 +12%
CPCM
8
Clifton Park Capital Management
Delaware
$47.6M
BIT
9
BlackRock Institutional Trust
California
$38.8M +$12M +221,458 +52%
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$36.2M -$3.75M -68,892 -10%
RG
11
Redmile Group
California
$34.5M +$5.49M +100,925 +21%
State Street
12
State Street
Massachusetts
$34.2M +$307K +5,652 +1%
VAM
13
Visium Asset Management
New York
$33.8M +$12.1M +223,125 +66%
BBA
14
Baker Bros. Advisors
New York
$32M +$12.5M +228,994 +76%
Adage Capital Partners
15
Adage Capital Partners
Massachusetts
$31.3M +$28.3M +519,365 New
Franklin Resources
16
Franklin Resources
California
$30.7M +$10.3M +189,400 +59%
BB
17
BB Biotech
Switzerland
$29.4M +$5.78M +106,302 +28%
SAM
18
Sectoral Asset Management
Quebec, Canada
$28.5M +$2.51M +46,200 +11%
QF
19
QVT Financial
New York
$24M +$2.93M +53,875 +16%
Lord, Abbett & Co
20
Lord, Abbett & Co
New Jersey
$23.7M +$5.11M +93,865 +31%
TCM
21
TimesSquare Capital Management
New York
$19.4M -$2.28M -41,900 -12%
ACH
22
ArrowMark Colorado Holdings
Colorado
$18.8M +$3.59M +66,046 +27%
Northern Trust
23
Northern Trust
Illinois
$17.3M +$2.47M +45,449 +19%
PIM
24
Partner Investment Management
California
$12.1M +$2.59M +47,611 +31%
Millennium Management
25
Millennium Management
New York
$12.1M +$7.89M +145,065 +263%

CLVS Hedge Fund Activity: Q4 2013 in Review

112 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2013, worth a combined $1.52B — up 11% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CLVS and 21 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 60 added.

The largest buyer was PFM Health Sciences, adding an estimated $30.3M. The largest seller was AllianceBernstein, cutting an estimated $23.4M.

  • 112 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2013, down from 116 in Q3 2013.
  • Funds reported $1.52B of Clovis Oncology, Inc. stock for Q4 2013, up 11% quarter-over-quarter.
  • 21 funds opened new Clovis Oncology, Inc. positions in Q4 2013 and 25 closed out, a net change of -4 holders.
  • The largest Clovis Oncology, Inc. buyer in Q4 2013 was PFM Health Sciences, an estimated $30.3M added.
  • The largest Clovis Oncology, Inc. seller in Q4 2013 was AllianceBernstein, an estimated $23.4M sold.

Based on aggregated 13F filings for Q4 2013.